Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GLS | O94925 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15724981 | 0.92 | ALDH1A1 (0.61) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15724982 | 0.92 | ALDH1A1 (0.61) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL17177109 | 0.92 | ALDH1A1 (0.61) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725005 | 0.88 | ALDH1A1 (0.64) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725101 | 0.88 | ALDH1A1 (0.64) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725013 | 0.85 | GLS (0.65) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725103 | 0.85 | GLS (0.65) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL20828251 | 0.85 | GLS (0.65) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725108 | 0.85 | GLS (0.59) | ALDH1A1TSHRGLSMEN1KMT2A | |
| SCHEMBL15725029 | 0.85 | GLS (0.59) | ALDH1A1TSHRGLSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689375-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190084976-A1 | COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084976-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | ALDH1A1 444/4885TSHR 4360/4885GLS 1/4885 |
| US-10689375-B2 | Compounds and their methods of use | GLS, GLS2, GLUL | ALDH1A1 444/4885TSHR 4360/4885GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.